ClinicalTrials.gg
RecruitingNCT07317154Updated Jul 10, 2026

Autologous Dendritic Cell Vaccine For Recurrent Respiratory Papillomatosis (RRP) Patients

A Phase 1 interventional study of Autologous HPV6 E6-and E7-derived peptide-loaded dendritic cell in Recurrent Respiratory Papillomatosis, sponsored by Mayo Clinic. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-10.

Sponsored by Mayo Clinic · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
9
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 20 studies in Recurrent respiratory papillomatosis with a site in United States — 8 open to participants now, 9 under way, 1 of them phase 3. Recurrent respiratory papillomatosis · United States.

Planned enrollment
13th of 16
9 · median 21
Started
2026
with 3 others
Phase 1
3 of 20
1 open now
Registered
17th of 20
by date
Lead sponsor
1 of 20
Mayo Clinic

Among the 20 studies in Recurrent respiratory papillomatosis with a site in United States, this one is the 13th largest by planned enrollment of the 16 interventional ones that give a count, is one of 4 that started in 2026, is one of 3 in phase 1, and was the 17th registered.

Recurrent respiratory papillomatosis

32 studies on the registry are indexed under Recurrent respiratory papillomatosis; 9 are open to participants now.

Browse Recurrent respiratory papillomatosis studies →

Open to participants now

8 of the 20 studies in Recurrent respiratory papillomatosis with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 6 Recurrent respiratory papillomatosis studies recruiting now, 5 set no upper age limit and none stop at 75 or younger; 2 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Recurrent respiratory papillomatosis with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and immunogenicity of autologous DC vaccine in recurrent respiratory papillomatosis patients

03

Conditions studied

  • Recurrent Respiratory Papillomatosis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinically confirmed diagnosis of recurrent respiratory papillomatosis.
  • Patients with papillomas in the laryngeal mucosa at the time of recruitment and patients with records of recurrent papillomas in laryngeal mucosa at least once in the past 6-12 months at the time of recruitment. NOTE: The presence of papillomas in laryngeal mucosa or clinical records of the presence of papillomas in laryngeal mucosa is required.
  • Human papilloma virus (HPV)6+ RRP in larynx
  • (Eastern cooperative oncology group performance test) performance status 0 or 1 (Appendix I).
  • The following laboratory values obtained ≤ 28 days prior to apheresis.

    • (ANC) ≥1.0 x 109 /L
    • count (PLT) ≥ 75 x 109 /L
    • ≥ 8.5 g/dL
    • Lymphocytes ≥ 0.3 x 109 /L
    • Total ≤ 2 x (ULN), unless patient has a documented history of Gilbert's disease, then Direct bilirubin ≤1.0 mg/dL.
    • (AST) ≤ 3 x ULN
    • Creatinine ≤ 2.0 mg/dL
    • Monocytes ≥ 0.25 x 109 /L
  • Able to provide informed written consent.
  • Willingness to return to Mayo Clinic Arizona for follow-up appointments
  • Willingness to provide blood samples for immune assessment and other tests
  • Willingness to provide papilloma tissues that will be surgically removed
  • Agree that during the trial, male participants will not father a child and female participants cannot be or become pregnant if they are of .
  • Subjects must fulfill one of the following conditions:

    • Agree to use one highly effective or combined method that results in a failure rate of methods must always be supplemented with the use of spermicide.
    • Be surgically sterile (vasectomy in males or absence of ovaries and/or uterus in females).
    • Be of non-childbearing potential (≥12 months of non-therapy-induced amenorrhea, confirmed by follicle stimulating hormone [FSH], if not on hormone replacement).

Exclusion criteria

Exclusion Criteria:

  • Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens.
  • patients and patients known to be positive and currently receiving antiretroviral therapy.
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  • Receiving any other approved or agent (including immune checkpoint blockers, immune modulators, and therapeutic vaccine models) for recurrent respiratory papillomatosis patients which would be considered as a treatment for the papillomas in laryngeal mucosa ≤ 6 months prior to study enrollment.
  • Other active ≤ 5 years prior to enrollment. NOTE: If there is a history or prior malignancy, with the exception of adequately treated basal cell or squamous cell carcinoma of the skin, they must not be receiving other specific treatment for their cancer within one year.
  • History of unstable heart disease including myocardial infarction ≤ 6 months prior to registration, congestive heart failure requiring use of ongoing maintenance therapy, significant cardiac dysfunction (left ventricular injection fraction 24 hours) documented by repeated measurement ≤ 4 weeks prior to registration
  • Diagnosis of disease, including, but not limited to, systemic lupus erythematosus, multiple sclerosis, rheumatoid arthritis, or ankylosing spondylitis.
  • Use of a systemic (> 5 mg prednisone daily or equivalent) ≤ 4 weeks prior to registration.
  • Pregnant or breastfeeding or planning on becoming pregnant during the study period.
  • Requirement for central line placement for cell collections.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
9 participants (estimated)

Study arms

  • Experimental
    Disease Group

    Patients with clinically confirmed human papilloma virus (HPV)6+ Recurrent Respiratory Papillomatosis (RRP) in the laryngeal mucosa at the time of recruitment, and patients with records of RRP in laryngeal mucosa at least once in the past 6-12 months at the time of recruitment, will receive immunotherapy.

    Biological: Autologous HPV6 E6-and E7-derived peptide-loaded dendritic cell

Interventions

  • BiologicalAutologous HPV6 E6-and E7-derived peptide-loaded dendritic cell

    Each patient will receive 5 doses autologous immunotherapy intradermally.

06

What researchers measure

Primary outcomes

  1. Number of participants with treatment-related adverse events

    Safety will be assessed as number of participants to experience adverse events, including systemic symptoms, irritation, inflammation, and any adverse events identified through physical exam and blood counts.

    Time frame: 20 months

Secondary outcomes

  1. Papilloma Resolution

    To evaluate the absence of laryngeal papilloma the number of laryngeal papilloma at completion of the treatment will be measured. This measurement will be compared to 3-year baseline data, or shorter based on date of diagnosis, for each patient as a self-control to interpret time and severity of recurrence.

    Time frame: 20 months

  2. Time to Disease Recurrence

    To measure time to disease recurrence of patients treated with autologous immunotherapy, the number of laryngeal papilloma during the treatment will be measured. This measurement will be compared to 3-year baseline data, or shorter based on date of diagnosis, for each patient as a self-control to interpret time and severity of recurrence.

    Time frame: 20 months

07

Study locations

1 of 1 sites recruiting
  • Mayo Clinic in Arizona
    Scottsdale, Arizona 85259, United States
    Recruiting
    • Debbie Ryan, CCRP · Contact480-342-1208
    • David G Lott, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2026; primary completion for Jun 2027, 9 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2025
First posted
Jan 5, 2026
StartEst.
Sep 2026
Primary completionEst.
Jun 2027
CompletionEst.
Dec 2027
Last update
Jul 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07317154
Lead sponsor
Mayo Clinic
Responsible party
David G. Lott, M.D. (Principal Investigator, Mayo Clinic) — Principal investigator
First posted
Jan 5, 2026
Start date
Sep 2026 (estimated)
Primary completion
Jun 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Jul 10, 2026

Study contacts

Debbie Ryan, CCRP
Contact
ryan.debra29@mayo.edu
480-342-1208
David G Lott, MD
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion